Infinity Pharma

INFI NASDAQ
1.650
-0.040
-2.37%
Closed 16:00 07/16 EDT
Open
1.640
Prev Close
1.690
High
1.670
Low
1.640
Volume
30.99K
Avg Vol (3M)
84.48K
52 Week High
2.920
52 Week Low
1.000
% Turnover
0.05%
Market Cap
93.93M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Infinity Pharma INFI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
MORE >

Recently

Name
Price
%Change